Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma - Concepedia

Concepedia

Publication | Open Access

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

DOI Full Paper Access

137

Citations

43

References

2021

Year

Paul Nghiem, Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Ragini R. Kudchadkar, Andrew S. Brohl, Philip Friedlander, Adil Daud, Harriet M. Kluger, Sunil Reddy,

Journal for ImmunoTherapy of Cancer

Abstract

NCT02267603.

References

	Year	Citations

Page 1